# US 2019/0153479 A1 · Recombinant microorganisms for enhanced production of mevalonate, isoprene, and isoprenoids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0153479 A1
- Document ID: US20190153479A1
- Status: Published application
- Kind: A1
- Application number: 16/200,485
- Filed: 2018-11-26
- Published: 2019-05-23
- Earliest claimed: 2011-04-29
- Assignees: Danisco US Inc.; The Goodyear Tire & Robber Company
- Applicants: Danisco US Inc.; The Goodyear Tire & Robber Company
- Inventors: Zachary Q. BECK; Michael C. MILLER; Caroline M. PERES; Yuliya A. PRIMAK; Jeff P. PUCCI; Derek H. WELLS
- Web page: https://patentgrep.com/patent/US20190153479A1

## CPC

- C12P 5/007: {containing one or more isoprene units, i.e. terpenes (carotenes C12P23/00)}
- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12N 9/0008: {acting on the aldehyde or oxo group of donors (1.2)}
- C12N 9/1025: {Acyltransferases (2.3)}
- C12N 9/1029: {transferring groups other than amino-acyl groups (2.3.1)}
- C12N 9/1217: {Phosphotransferases with a carboxyl group as acceptor (2.7.2)}
- C12N 9/18: Carboxylic ester hydrolases {(3.1.1)}
- C12N 9/88: Lyases (4.)
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12P 5/002: {cyclic (compounds containing at least three condensed carbocyclic rings C12P15/00)}
- C12P 5/026: {Unsaturated compounds, i.e. alkenes, alkynes or allenes}
- C12P 7/02: containing a hydroxy group
- C12P 7/04: acyclic
- C12P 7/42: Hydroxy-carboxylic acids
- C12Y 101/01027: L-Lactate dehydrogenase (1.1.1.27)
- C12Y 101/01034: Hydroxymethylglutaryl-CoA reductase (NADPH) (1.1.1.34)
- C12Y 101/01037: Malate dehydrogenase (1.1.1.37)
- C12Y 102/01051: Pyruvate dehydrogenase (NADP+) (1.2.1.51)
- C12Y 102/04001: Pyruvate dehydrogenase (acetyl-transferring) (1.2.4.1)
- C12Y 203/01008: Phosphate acetyltransferase (2.3.1.8)
- C12Y 203/01016: Acetyl-CoA C-acyltransferase (2.3.1.16)
- C12Y 203/03001: Citrate (Si)-synthase (2.3.3.1)
- C12Y 203/0301: Hydroxymethylglutaryl-CoA synthase (2.3.3.10)
- C12Y 207/02001: Acetate kinase (2.7.2.1)
- C12Y 301/01031: 6-Phosphogluconolactonase (3.1.1.31)
- C12Y 401/01031: Phosphoenolpyruvate carboxylase (4.1.1.31)
- Y02E 50/30: Fuel from waste, e.g. synthetic alcohol or diesel
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- Y02E: REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION

## Abstract

The invention features compositions and methods for the increased production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids in microorganisms by engineering a microorganism for increased carbon flux towards mevalonate production in the following enzymatic pathways: (a) citrate synthase, (b) phosphotransacetylase, (c) acetate kinase, (d) lactate dehydrogenase, (e) malic enzyme, and (f) pyruvate dehydrogenase such that one of more of the enzyme activity is modulated. In addition, production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids can be further enhanced by the heterologous expression of the mvaE and mvaS genes (such as, but not limited to, mvaE and mvaS genes from the organisms Listeria grayi DSM 20601, Enterococcus faecium, Enterococcus gallinarum EG2, and Enterococcus casseliflavus).

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

Recombinant cells capable of increased production of mevalonate, wherein the cells comprise:
(i) modulated activity of three or more enzymes from the group consisting of:
(a) decreased activity of citrate synthase,
(b) attenuated activity of phosphotransacetylase,
(c) attenuated activity of acetate kinase,
(d) attenuated activity of lactate dehydrogenase,
(e) increased activity of malate dehydrogenase,
(f) increased activity of pyruvate dehydrogenase,
(g) attenuated activity of phosphogluconolactonase (PGL), and
(h) attenuated activity of phosphoenolpyruvate carboxylase, resulting in increased carbon flux towards mevalonate production; and
(ii) one or more nucleic acids encoding one or more upper mevalonate (MVA) pathway polypeptides; and wherein the cells produce increased amounts of mevalonate compared to mevalonate-producing cells that do not comprise (i) and (ii).

### Claim 21 (depends on 20)

The cells of claim 20, wherein the one or more nucleic acids encoding an upper MVA pathway polypeptide are an mvaE gene and an mvaS gene.

### Claim 22 (depends on 21)

The cells of claim 21, wherein the mvaE gene and the mvaS gene are selected from the group consisting of: (a) an mvaE gene and an mvaS gene from L. grayi; (b) an mvaE gene and an mvaS gene from E. faecium; (c) an mvaE gene and an mvaS gene from E. gallinarum; (d) an mvaE gene and an mvaS gene from E. casseliflavus; and (e) an mvaE gene and an mvaS gene from E. faecalis.

### Claim 23 (depends on 20)

The cells of claim 20, wherein the activity of citrate synthase is decreased by decreasing the expression of an endogenous citrate synthase gene.

### Claim 24 (depends on 20)

The cells of claim 20, wherein the activity of phosphotransacetylase and/or acetate kinase is attenuated by attenuating the expression of an endogenous phosphotransacetylase gene and/or an endogenous acetate kinase gene.

### Claim 25 (depends on 20)

The cells of claim 20, wherein the activity of lactate dehydrogenase is attenuated by attenuating the expression of an endogenous lactate dehydrogenase gene.

### Claim 26 (depends on 20)

The cells of claim 20, wherein the activity of malate dehydrogenase is increased by increasing the expression of a malate dehydrogenase gene.

### Claim 27 (depends on 20)

The cells of claim 20, wherein the activity of pyruvate dehydrogenase is increased by increasing the expression of one or more genes of the pyruvate dehydrogenase complex consisting of (a) pyruvate dehydrogenase (E1), (b) dihydrolipoyl transacetylase, and (c) dihydrolipoyl dehydrogenase.

### Claim 28 (depends on 20)

The cells of claim 20, wherein the activity of PGL is attenuated by attenuating the expression of an endogenous PGL gene.

### Claim 29 (depends on 20)

The cells of claim 20, wherein the activity of phosphoenolpyruvate carboxylase is attenuated by attenuating the expression of an endogenous phosphoenolpyruvate carboxylase gene.

### Claim 30 (depends on 20)

A method of producing mevalonate, comprising: (a) culturing the cells of claim 20 under suitable culture conditions for production of mevalonate; and (b) producing the mevalonate.

### Claim 31 (depends on 30)

The method of claim 30, further comprising (c) recovering the mevalonate.

### Claim at position 14

32-48. (canceled)

### Claim 49 (depends on 20)

The cells of claim 20, wherein the modulated activity of three or more enzymes comprises:
(I) decreased activity of citrate synthase;
(II) attenuated activity of one or more of (A) phosphotransacetylase, (B) acetate kinase, and (C) lactate dehydrogenase; and
(III) modulated activity of one or more enzymes from the group consisting of (D) increased activity of malate dehydrogenase, (E) increased activity of pyruvate dehydrogenase, and (F) attenuated activity of phosphoenolpyruvate carboxylase.

### Claim 50 (depends on 49)

The cells of claim 49, wherein the (III) modulated activity of one or more enzymes comprises (E) increased activity of pyruvate dehydrogenase.

### Claim 51 (depends on 20)

The cells of claim 20, wherein the cells are gram-positive bacterial cells, Streptomyces cells, gram-negative bacterial cells, Escherichia cells, Pantoea cells, or yeast cells.

### Claim 52 (depends on 51)

The cells of claim 51, wherein the cells are Bacillus subtilis cells, Escherichia coli cells, or Pantoea citrea cells.

### Claim 53 (depends on 51)

The cells of claim 51, wherein the cells are Saccharomyces cerevisiae cells.
